中文(ZH) 一品红：全资子公司创新药APH03867片获得临床试验注册申请受理

一品红子公司候选药物APH03867获批临床试验

作者 PulseAugur 编辑部 · [1 个来源] · 2026-06-18 04:26

一品红子公司广州一品红医药有限公司的创新药APH03867已获得国家药品监督管理局的临床试验注册申请受理。这标志着该药物的开发过程迈出了重要一步。另外，上海延诚贸易有限公司的领导层发生变动，宗科丽被任命为法定代表人兼经理，浙江红一控股集团有限公司为唯一股东。 AI

排序理由该集群报道了候选药物获得监管机构批准进行临床试验，属于研发里程碑。 [lever_c_demoted from research: ic=1 ai=0.1]

AI 生成摘要 · Google Gemini · 来自 1 个来源。我们如何撰写摘要 →

本文如何被排名

Signal score: 0 / 100; Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket: Tool; 该集群报道了候选药物获得监管机构批准进行临床试验，属于研发里程碑。 [lever_c_demoted from research: ic=1 ai=0.1]
Source corroboration: Single-source cluster; Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics: product, other; Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance: Low; Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness: 95 days old; Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。

36氪 (36Kr) TIER_1 中文(ZH) · 2026-06-18 04:26

一品红：全资子公司创新药APH03867片获临床试验注册申请受理

36氪获悉，一品红公告，全资子公司广州一品红制药有限公司自主研发的创新药物APH03867片的药物临床试验申请获得国家药品监督管理局受理，并收到《受理通知书》。